Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $290,403 | $232,261 | $176,954 | $140,800 |
| % Growth | 25% | 31.3% | 25.7% | – |
| Cost of Goods Sold | $44,522 | $35,765 | $28,448 | $23,658 |
| Gross Profit | $245,881 | $196,496 | $148,506 | $117,142 |
| % Margin | 84.7% | 84.6% | 83.9% | 83.2% |
| R&D Expenses | $48,062 | $32,443 | $24,047 | $17,772 |
| G&A Expenses | $5,276 | $4,855 | $4,467 | $4,050 |
| SG&A Expenses | $67,377 | $61,598 | $50,684 | $41,058 |
| Sales & Mktg Exp. | $62,101 | $56,743 | $46,217 | $37,008 |
| Other Operating Expenses | $2,103 | -$119 | -$1,034 | -$332 |
| Operating Expenses | $117,542 | $93,922 | $73,697 | $58,498 |
| Operating Income | $128,339 | $102,574 | $74,809 | $58,644 |
| % Margin | 44.2% | 44.2% | 42.3% | 41.7% |
| Other Income/Exp. Net | -$1,148 | $2,100 | -$5,558 | $436 |
| Pre-Tax Income | $127,191 | $104,674 | $69,251 | $59,080 |
| Tax Expense | $26,203 | $20,991 | $13,537 | $11,323 |
| Net Income | $100,988 | $83,683 | $55,525 | $47,757 |
| % Margin | 34.8% | 36% | 31.4% | 33.9% |
| EPS | 22.68 | 9.34 | 12.26 | 10.4 |
| % Growth | 142.8% | -23.8% | 17.9% | – |
| EPS Diluted | 22.64 | 9.31 | 12.22 | 10.37 |
| Weighted Avg Shares Out | 4,454 | 4,494 | 4,531 | 4,593 |
| Weighted Avg Shares Out Dil | 4,461 | 4,495 | 4,545 | 4,605 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,838 | $1,069 | $239 | $231 |
| Interest Expense | $1,640 | $739 | $378 | $289 |
| Depreciation & Amortization | $8,545 | $5,825 | $5,306 | $5,311 |
| EBITDA | $137,376 | $111,041 | $76,802 | $64,826 |
| % Margin | 47.3% | 47.8% | 43.4% | 46% |